Checkmate Pharmaceuticals

Checkmate Pharmaceuticals EBIT

Delisted

The EBIT of Checkmate Pharmaceuticals (CMPI) as of Oct 14, 2026 is -61.47 M USD. In the previous year, EBIT was -36.90 M USD — a change of 66.57% (lower).

EBIT

-61.47 MUSD

YoY

66.57%

Last updated:

In 2021, Checkmate Pharmaceuticals's EBIT was -61.47 M USD, a 66.57% increase from the -36.90 M USD EBIT recorded in the previous year.

The Checkmate Pharmaceuticals EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2019
-28.89 M USD
Jan 1, 2020
-36.90 M USD
Jan 1, 2021
-61.47 M USD
Jan 1, 2022 (e)
-71.41 M USD
Jan 1, 2023 (e)
-82.55 M USD
Jan 1, 2024 (e)
-148.54 M USD
Jan 1, 2025 (e)
-76.06 M USD
Jan 1, 2026 (e)
-39.73 M USD
The Checkmate Pharmaceuticals EBIT history
YEAREBITYoY
est-39.73 MUSD-47.77%
est-76.06 MUSD-48.79%
est-148.54 MUSD+79.94%
est-82.55 MUSD+15.60%
est-71.41 MUSD+16.17%
-61.47 MUSD+66.57%
-36.90 MUSD+27.74%
-28.89 MUSD+37.61%
-20.99 MUSD—
Access this data via the Eulerpool API

Checkmate Pharmaceuticals Revenue

Checkmate Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
0.00 USD
-28.89 M USD
-28.29 M USD
Jan 1, 2020
0.00 USD
-36.90 M USD
-36.91 M USD
Jan 1, 2021
0.00 USD
-61.47 M USD
-61.41 M USD
Jan 1, 2022 (e)
0.00 USD
-71.41 M USD
-66.56 M USD
Jan 1, 2023 (e)
0.00 USD
-82.55 M USD
-50.25 M USD
Jan 1, 2024 (e)
46.77 M USD
-148.54 M USD
-95.99 M USD
Jan 1, 2025 (e)
48.14 M USD
-76.06 M USD
-64.63 M USD
Jan 1, 2026 (e)
50.55 M USD
-39.73 M USD
-44.38 M USD

Checkmate Pharmaceuticals Margins

Checkmate Pharmaceuticals stock margins

The Checkmate Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Checkmate Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Checkmate Pharmaceuticals.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
0.00 %
- %
- %
Jan 1, 2020
0.00 %
- %
- %
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022 (e)
0.00 %
- %
- %
Jan 1, 2023 (e)
0.00 %
- %
- %
Jan 1, 2024 (e)
0.00 %
-317.63 %
-205.26 %
Jan 1, 2025 (e)
0.00 %
-158.00 %
-134.25 %
Jan 1, 2026 (e)
0.00 %
-78.59 %
-87.80 %

Checkmate Pharmaceuticals Stock analysis

What does Checkmate Pharmaceuticals do? Checkmate Pharmaceuticals Inc is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2015 and specializes in the research and development of immuno-oncology therapies. The company has an innovative business model aimed at improving the immune response against cancer. It utilizes the natural ability of the immune system to recognize and eliminate cancer cells. Immuno-oncology is a major trend in cancer therapy today, with the goal of harnessing the body's own immune system to fight cancer cells. Checkmate Pharmaceuticals focuses on the development of unique first-in-class immunotherapeutics. The company collaborates closely with leading academic institutions and international organizations to maximize the potential of its technology and achieve the best results. The business of Checkmate Pharmaceuticals can be divided into three areas, from the Checkmate platform technology, for which multiple patents have been filed, to the two products: CMP-001 (classified as Breakthrough Therapy) and CMP-003. The Checkmate platform technology is based on stimulating immune responses through the ligation of oligonucleotides, which in turn is intended to promote the recognition and elimination of cancer cells. This method aims to safely and effectively harness the benefits of immunotherapy and successfully control the potential hazards of the immune system. CMP-001 is an immunotherapeutic currently in phase 2a clinical development. It is a combination of an adjuvant called STING agonists (also known as Sting-Signalling agonist) and a toll-like receptor-ligand of nucleotide (TLR-9), which help stimulate the body's immune system and trigger an immune response against cancer cells. CMP-001 has been granted 'Breakthrough Therapy' status by the US FDA, meaning that the drug offers a significant advancement in the treatment of patients with serious or life-threatening diseases compared to currently available therapies. CMP-003 is another development by Checkmate Pharmaceuticals, aiming to regulate excessive immune response. Along with STING, antibodies against poxviruses have been shown to activate the immune system and enable effective tumor therapy. One of the main target populations for Checkmate Pharmaceuticals is patients with various types of tumors such as melanoma, small cell lung cancer, and solid tumors that respond to immune system stimulation. Currently, the company is financed by renowned capital investors such as F-Prime Capital, HBM Healthcare Investments, and Sofinnova Investments. The company offers promising perspectives in cancer research and has the potential to deliver further advancements in the field of immuno-oncology with new products. These developments can help make cancer therapy more effective and safer, ultimately moving towards the goal of fighting cancer. Checkmate Pharmaceuticals is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Checkmate Pharmaceuticals's EBIT

Checkmate Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Checkmate Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Checkmate Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Checkmate Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Checkmate Pharmaceuticals stock

EBIT of Checkmate Pharmaceuticals is -61.47 M USD in 2021.

EBIT of Checkmate Pharmaceuticals changed from -36.90 M USD to -61.47 M USD, representing a 66.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Checkmate Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Checkmate Pharmaceuticals historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Checkmate Pharmaceuticals

All Key Metrics — Checkmate Pharmaceuticals